Aditxt Inc ADTX

New Press Release - Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally

[PressRelease]

Evofem posted $13.4 million in net sales of Phexxifor the first nine months of 2023;Aditxt looks to accelerate Evofem into the global non-hormonal birth control market valued at $27.7 billion in 2022 and is projected to grow to $52.2 billion by 2031 Aditxt, Inc. (“Aditxt” or the “Company...read article.